(FM) Oncología
Departamento académico
Dana–Farber Cancer Institute
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (26)
2023
-
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
Gynecologic Oncology, Vol. 178, pp. 119-129
-
Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 609-617
-
Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Obstetrical and Gynecological Survey
-
Safety and management of niraparib monotherapy in ovarian cancer clinical trials
International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 971-981
2022
-
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
Journal for immunotherapy of cancer, Vol. 10, Núm. 5
-
EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)
Future oncology (London, England), Vol. 18, Núm. 31, pp. 3481-3492
-
Niraparib treatment for patients with BRCA-mutated ovarian cancer: Review of clinical data and therapeutic context
Future Oncology, Vol. 18, Núm. 23, pp. 2505-2536
2021
-
Considerations for treatment duration in responders to immune checkpoint inhibitors
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3
-
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 5, pp. 632-642
-
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
Gynecologic Oncology, Vol. 163, Núm. 1, pp. 41-49
2020
-
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Nature Medicine, Vol. 26, Núm. 6, pp. 878-885
-
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Cancer Cell, Vol. 38, Núm. 4, pp. 500-515.e3
-
Efficacy of Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer with a BRCA Mutation: Subgroup Analysis Findings from the SOLO1 Trial
Journal of Clinical Oncology, Vol. 38, Núm. 30, pp. 3528-3537
-
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
Journal of Thoracic Oncology, Vol. 15, Núm. 4, pp. 618-627
-
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
Gynecologic Oncology, Vol. 157, Núm. 2, pp. 379-385
2019
-
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
Annals of Oncology, Vol. 30, Núm. 7, pp. 1080-1087
-
Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer
Obstetrical and Gynecological Survey
2018
-
Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer
New England Journal of Medicine, Vol. 379, Núm. 26, pp. 2495-2505
-
Safety and dose modification for patients receiving niraparib
Annals of Oncology, Vol. 29, Núm. 8, pp. 1784-1792
2017
-
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Obstetrical and Gynecological Survey